Servier, buoyed by high-performance R&D, confirms its 2025 trajectory to achieve its 2030 ambition
All the news from Servier Group
Servier and Aitia Announce a New Collaboration Focused on Parkinson’s Disease
Nicolas Garnier joins Servier as Chief Patient Officer
Servier partners with Owkin with the aim of discovering and developing AI-driven precision therapeutics
Servier launches senior skills-based sponsorship program
Servier is launching the sixth edition of the global awareness campaign “#BecauseIsayso” “#Takeyourmedicine” focused on adherence to treatment
Aitia Enters into Multi-Year AI Driven Drug Discovery and Drug Simulation Collaboration with Servier for Pancreatic Cancer
Changes to the Executive Committee of Servier Group
Specifica Announces Antibody Discovery Platform Transfer Agreement with Servier and its Subsidiary Symphogen